Gilead Sciences | GILD - Selling And Administration Expenses

Stock Price
140.41
Daily Change
1.04 0.75%
Monthly
-6.41%
Yearly
25.49%
Q2 Forecast
130.22

Gilead Sciences reported $1.78B in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
ALKERMES USD 187.2M 15.43M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
J&J USD 6.75B 831M Dec/2025
Merck USD 2.85B 215M Dec/2025
Moderna USD 308M 40M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
United Therapeutics USD 190.6M 38.6M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025